Grafa
AC Immune reports positive interim data from ABATE trial of ACI-24
Image for illustrative purposes only. Not a real photo.

AC Immune reports positive interim data from ABATE trial of ACI-24

Share
  • AC Immune (NASDAQ:ACIU) reported 12-month interim data from the Phase 1b/2 ABATE trial of ACI-24 in patients with prodromal Alzheimer’s disease.
  • ACI-24 was generally safe and well tolerated, with no ARIA-E, and showed anti-Aβ antibody responses at all dose levels.
  • A new AD4 cohort is testing an added adjuvant to enhance immunogenicity.

AC Immune (NASDAQ:ACIU) reported 12-month interim data from the Phase 1b/2 ABATE trial of ACI-24 in 74 patients with prodromal Alzheimer’s disease across cohorts AD1-AD3.

According to the company, ACI-24 has been generally safe and well tolerated, with no ARIA-E observed.

The vaccine candidate showed anti-Aβ antibody responses at all dose levels, with evidence of a dose response.

A new AD4 cohort is testing an added adjuvant to enhance immunogenicity.

The data support continued development of ACI-24 as a potential active immunotherapy for early Alzheimer’s disease.

AC Immune is focused on developing precision therapies and diagnostics for neurodegenerative diseases, with ACI-24 as a key program in its Alzheimer’s pipeline.

The company continues to advance its vaccine-based approach to addressing amyloid pathology in Alzheimer’s disease.

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.